The heat on healthcare’s middlemen — pharmacy benefit managers (PBM) — is increasing, but a tangible solution may still be far off. Lawmakers grilled PBM executives Tuesday at the third hearing in a ...
Forbes contributors publish independent expert analyses and insights. I write about business model strategy and execution across healthcare. Corrected, July 23, 2024: An earlier version of this ...
In a conversation hosted by DSN, EmpiRx Health CEO Danny Sanchez and EmpiRx Health President John Ridyard detailed how their mid-market PBM is gaining traction by putting pharmacists at the center of ...
The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen. The ...
The House Committee on Oversight and Government Reform said last week that it’s expanding its investigation into the role of pharmacy benefit managers by seeking information about how they use foreign ...
About two years after launching an investigation into pharmacy benefit managers, the Federal Trade Commission has finally released some of its findings — and they don’t bode well for the prescription ...
Bipartisan policies in Congress meant to lower drug costs by targeting middlemen in the pharmaceutical supply chain are likely to run up against a fundamental issue: the three major pharmacy benefit ...
This article is part of a monthly column that considers the significance of recent Federal Trade Commission announcements about antitrust issues. In this installment, we discuss the FTC's complaint on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results